Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 293.2 SEK -3.3%
Market Cap: 104.4B SEK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SOBI stock under the Base Case scenario is 497.68 SEK. Compared to the current market price of 293.2 SEK, Swedish Orphan Biovitrum AB (publ) is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOBI Relative Value
Base Case
497.68 SEK
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
28
vs Industry
66
Median 3Y
3.8
Median 5Y
3.7
Industry
7.1
Forward
3.5
More Details
25.4
P/E
P/E
Price to Earnings
25.4
vs History
30
vs Industry
6
Median 3Y
26.6
Median 5Y
24
Industry
23
Forward
18.9
More Details
13.5
P/OCF
P/OCF
Price to OCF
13.5
vs History
44
vs Industry
12
Median 3Y
14.6
Median 5Y
13.6
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
7
Median 5Y
6.6
Industry
23.1
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
38
vs Industry
36
Median 3Y
2.6
Median 5Y
2.6
Industry
2.6
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
41
vs Industry
54
Median 3Y
4.2
Median 5Y
4.2
Industry
7.5
Forward
3.8
More Details
5.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.3
vs History
46
vs Industry
54
Median 3Y
5.6
Median 5Y
5.5
Industry
9.4
More Details
11.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.5
vs History
44
vs Industry
11
Median 3Y
12.1
Median 5Y
11.6
Industry
4.4
Forward
10.2
More Details
18.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.9
vs History
34
vs Industry
7
Median 3Y
19.7
Median 5Y
17.6
Industry
4.5
Forward
15.3
More Details
14.7
EV/OCF
EV/OCF
Enterprise Value to OCF
14.7
vs History
47
vs Industry
11
Median 3Y
16.2
Median 5Y
15.2
Industry
5.2
More Details
21.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.2
vs History
55
vs Industry
6
Median 3Y
23.6
Median 5Y
23.6
Industry
3.7
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
9
vs Industry
50
Median 3Y
1.5
Median 5Y
1.5
Industry
4.8
More Details

Multiples Across Competitors

SOBI Competitors Multiples
Swedish Orphan Biovitrum AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
100.5B SEK 3.8 25.4 11.5 18.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 476 503.8 -163 861.7 -198 980.4 -196 709.8
US
Abbvie Inc
NYSE:ABBV
341.1B USD 5.9 82.1 15.6 23
US
Amgen Inc
NASDAQ:AMGN
159B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136B USD 4.7 22.8 9.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.4B USD 10.6 -118.7 25.2 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 043.4 -521.4 -567.8 -552.6
AU
CSL Ltd
ASX:CSL
116.7B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.5B USD 4 12.6 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 19.7 -60.4 -65 -58.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.6B USD 16.9 -146.8 -657 -329.2
P/E Multiple
Earnings Growth PEG
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average P/E: 32.9
25.4
30%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 861.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
82.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.8
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -146.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average EV/EBITDA: 15
11.5
15%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 980.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.6
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -657 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average EV/EBIT: 20
18.9
24%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 709.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.6 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.2 N/A N/A

See Also

Summary
SOBI intrinsic value, competitors valuation, and company profile.
DCF Valuation
SOBI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SOBI stock valuation using valuation multiples.
Wall Street Estimates
SOBI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SOBI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.